Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | HK1 | P19367 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PARG | Q86W56 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27804433 | 0.85 | TDP2 (0.38) | TDP2NSD2HK1PAX8GAA | |
| SCHEMBL27171469 | 0.81 | PKM (0.40) | TDP2NSD2HK1PAX8GAA | |
| SCHEMBL27804432 | 0.78 | PARG (0.33) | TDP2NSD2HK1PAX8GAA | |
| SCHEMBL27171484 | 0.73 | PKM (0.39) | TDP2NSD2HK1PAX8GAA | |
| SCHEMBL55488 | 0.72 | TDP2 (0.40) | TDP2NSD2HK1PAX8GAA | |
| SCHEMBL10775524 | 0.66 | TDP2 (0.67) | TDP2NSD2HK1PAX8GAA | |
| SCHEMBL7339146 | 0.66 | TDP2 (0.67) | TDP2NSD2HK1PAX8GAA | |
| SCHEMBL27171477 | 0.66 | PKM (0.38) | GAAMAPTPOLBPKMMEN1 | |
| SCHEMBL27171459 | 0.66 | POLB (0.36) | TDP2NSD2HK1PAX8GAA | |
| SCHEMBL27171478 | 0.65 | TDP2 (0.38) | TDP2NSD2HK1PAX8GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446021-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| EP-2152258-B1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | DOGWOOD PHARMACEUTICALS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9120754-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120129837-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | ALLERGAN SALES, LLC | 2012-05-24 | — | — | US | disclosed |
| US-8129519-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | ALLERGAN SALES, LLC | 2012-03-06 | — | — | US | disclosed |
| WO-2010082912-A1 | DERIVATIVES OF MULTI-RING AROMATIC COMPOUNDS AND USES AS ANTI-TUMOR AGENTS | AVALON PHARMACEUTICALS (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | ALLERGAN SALES, LLC | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129837-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | WNT1, CTNND1, CTNNB1 | TDP2 3475/4885NSD2 381/4885HK1 1185/4885 |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | WNT1, CTNND1, CTNNB1 | TDP2 3475/4885NSD2 381/4885HK1 1185/4885 |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | WNT1, CTNND1, CTNNB1 | TDP2 3475/4885NSD2 381/4885HK1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.